The Aperlena Verdict
Open raceNo supplier dominates: 37 different companies have won the last 88 comparable contracts from this buyer over 5 years. This is a genuinely open race.
- -0.1%
- Expected final price vs the published estimate
Based on 88 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.
Summary
Machine-generated summaryThis Czech public procurement concerns medicinal products and medical devices, specifically medicinal products containing the active substance emicizumab. The subject of the procurement is the conclusion of a framework purchase agreement for the supply of these medicinal products according to the needs of the contracting authority. Supplies are to be delivered as required over the duration of the framework agreement, which allows the buyer to order quantities flexibly depending on actual demand. Emicizumab is a medicine used in the treatment of haemophilia, so the agreement is intended to secure a stable source of this therapy for the contracting authority. The notice does not subdivide the procurement into lots.
Description
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 2 days ago
More from this buyer
Full buyer profile35 open tenders right now
- Medicinal products and medical devices - Medicinal product with active substance ERDAFITINIB 1 day left
- Czech Republic - Medicinal products and medical devices - Medicinal products with active substance USTEKINUMAB II. 1 day left
- Medicinal products and medical devices - Medicinal product with active substance MOMELOTINIB 1 day left
Who usually wins this buyer's contracts in this sector
| Company | Wins | Total awarded | Last win |
|---|---|---|---|
| PHOENIX lékárenský velkoobchod, s.r.o. | 17 | €51.3M | Aug 2026 |
| Alliance Healthcare s.r.o. | 16 | €24.5M | Aug 2026 |
| ROCHE s.r.o. | 6 | €19.9M | Jul 2026 |
| ELI LILLY ČR, s.r.o. | 5 | €4.8M | Aug 2026 |
| Takeda Pharmaceuticals Czech Republic s.r.o. | 3 | €12.7M | May 2026 |
Based on 88 awards with a linked company profile over the last 5 years.
What this buyer has paid before
Based on 90 comparable contracts this buyer awarded in this sector over the last 4 years.
- €221,341
- Lower quartile
- €632,413
- Median award
- €1.6M
- Upper quartile
Most recent awards
- Česko - Léčivé přípravky a zdravotnické prostředky - Léčivé přípravky s účinnou látkou SELPERKATINIB €1,158,443
- Česko - Léčivé přípravky a zdravotnické prostředky - Léčivé přípravky s účinnou látkou IVOSIDENIB €2,637,652
- Česko - Léčivé přípravky a zdravotnické prostředky - Léčivé přípravky s účinnou látkou BUDESONID - výdej pro veřejnost II €200,596
- Česko - Léčivé přípravky a zdravotnické prostředky - Léčivý přípravek s účinnou látkou GILTERITINIB-FUMARÁT €1,864,261
- Česko - Léčivé přípravky a zdravotnické prostředky - Léčivý přípravek s účinnou látkou AFLIBERCEPT €1,419,506
Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.
Similar tenders
1
day left
€290,468
est. value
1
day left
€674,542
est. value
1
day left
€5,736,062
est. value
1
day left
€1,254,163
est. value
Market context
- Avg. open tender · Medical equipment & pharmaceuticals
- €10,072,234
- Buyer track record on Aperlena
- 455 notices tracked · 161 awarded
- €340,824,584 in awarded contracts
Never miss a tender like this
177 new notices in Medical equipment & pharmaceuticals in Czechia in the last 7 days. Get an email when new ones appear. Free.
Set up my alert